Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Solubility of Ionic Compounds02:55

Solubility of Ionic Compounds

Solubility is the measure of the maximum amount of solute that can be dissolved in a given quantity of solvent at a given temperature and pressure. Solubility is usually measured in molarity (M) or moles per liter (mol/L). A compound is termed soluble if it dissolves in water.
Sugars as Energy Storage Molecules01:10

Sugars as Energy Storage Molecules

Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Structural Isomerism02:34

Structural Isomerism

Isomerism in Complexes
Isomers are different chemical species that have the same chemical formula. Structural isomerism of coordination compounds can be divided into two subcategories, the linkage isomers and coordination-sphere isomers.
Linkage isomers occur when the coordination compound contains a ligand that can bind to the transition metal center through two different atoms. For example, the CN− ligand can bind through the carbon atom or through the nitrogen atom. Similarly, SCN− can be...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review investigating the safety and efficacy of intravenous iron in people with ND-CKD who are iron deficient but not anaemic.

Clinical kidney journal·2026
Same author

Indicators of Safety and Wellbeing in Patients Starting Maintenance Haemodialysis Using Phased Approach: Findings from a Cohort Feasibility Study.

Healthcare (Basel, Switzerland)·2026
Same author

New Insights Into Delaying Renal Progression: Cardiovascular, Renal & Metabolic Medicine.

British journal of hospital medicine (London, England : 2005)·2026
Same author

A Digital Inclusion Intervention to Improve Access to a Digital Health Intervention Among Digitally Excluded Adults: Mixed Methods Pilot Randomized Controlled Trial.

JMIR formative research·2026
Same author

Phased Introduction of Haemodialysis in Patients with Kidney Failure: A Mixed-Methods Feasibility Study.

Healthcare (Basel, Switzerland)·2026
Same author

Awareness and attitudes towards ayurveda in chronic disease management and related knowledge gaps among UK healthcare professionals: an analytical cross-sectional survey.

BMC complementary medicine and therapies·2026

Related Experiment Video

Updated: May 10, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
04:40

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

Iron (III) isomaltoside 1000.

Thomas A R Mace1, Ahsan Syed, Sunil Bhandari

  • 1Hull York Medical School, Hertford Building, University of Hull, Hull, HU6 7RX, UK. sunil.bhandari@hey.nhs.uk

Expert Review of Hematology
|June 21, 2013
PubMed
Summary

Iron isomaltoside, a new intravenous iron, shows promise for treating iron deficiency anemia, particularly in patients with chronic kidney disease and heart failure. Further comparative studies are needed to confirm its efficacy and safety against existing treatments.

More Related Videos

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues
09:27

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues

Published on: February 17, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
04:40

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues
09:27

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues

Published on: February 17, 2017

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Intravenous (IV) iron is recommended for iron deficiency anemia when oral iron fails or in hemodialysis patients.
  • Iron isomaltoside is a novel IV iron preparation with a unique nonionic isomaltoside carbohydrate matrix, designed for low immunogenicity and high single-dose infusions.
  • Concerns exist regarding potential renal injury from IV iron preparations due to oxidative stress.

Purpose of the Study:

  • To investigate the safety and efficacy profile of iron isomaltoside in patients with chronic kidney disease (CKD) and chronic heart failure (CHF).
  • To assess the potential for reduced renal damage with iron isomaltoside compared to older IV iron preparations.
  • To evaluate the cost-effectiveness of iron isomaltoside in clinical practice.

Main Methods:

  • Two Phase III, open-label, noncomparative, multicenter clinical trials were conducted.
  • The trials focused on patients with CKD and CHF receiving iron isomaltoside.
  • Safety events, hemoglobin levels, serum ferritin, and quality of life were monitored.

Main Results:

  • Significant increases in hemoglobin and serum ferritin were observed in the CKD group.
  • The CHF group showed a significant rise in serum ferritin and improved quality of life, but a nonsignificant hemoglobin increase.
  • Two serious adverse events (sepsis, angina) were reported, with questionable drug relationship. Modern IV iron preparations like iron isomaltoside may theoretically cause less renal damage due to reduced free iron release.

Conclusions:

  • Iron isomaltoside demonstrates encouraging initial safety and efficacy data, particularly for replenishing iron stores in CKD and CHF patients.
  • While potentially more cost-effective due to faster infusion rates, current data is limited, necessitating further research.
  • Comparative studies are crucial to establish the superiority of iron isomaltoside over existing IV iron therapies.